# Cancer Pharmacokinetics and Pharmacodynamics Facility

> **NIH NIH P30** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2020 · $220,455

## Abstract

Abstract: Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF)
The Hillman Cancer Center (HCC) Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) is an
important shared resource that supports science conducted by the HCC research programs and has a major
impact on cancer drug development on a national level by providing state-of-the-art and comprehensive
quantitative and qualitative bioanalytical support for preclinical and clinical cancer therapeutic studies. The
activities of CPPF have earned national recognition for its exceptional service in developing and delivering
PK and PD analyses of investigational agents.
CPPF: (1) provides extensive pharmacology expertise to investigators by assisting in PK and PD study design
and sample collection; (2) develops and provides quality-assured/quality-controlled quantitative and qualitative
assay capabilities for rapid and efficient PK and PD bioanalyses; and (3) integrates PK/PD data through
sophisticated data analyses.
CPPF is located in two contiguous lab spaces with a shared office pod in the HCC Research Pavilion. Major
equipment includes 3 Waters QuattroMicro LC-MS/MS, 2 SCIEX4000 LC-MS/MS (1 hybrid linear ion-trap), 2
HPLC-UV/FL/DAD, 1 HPLC-UV/RAD, 1 atomic absorption spectrometer, a LICOR Odyssey infra-red scanner,
a Tecan Infinite Microplate Reader, and a Nexcelom Cellometer K2 Cell counter. Ancillary equipment includes
-20 °C and -80 °C freezers, a nitrogen generator, and an uninterrupted power supply, as well as access to
shared instrumentations including a liquid scintillation counter.
CPPF is directed by Drs. Jan Beumer, Professor of Pharmaceutical Sciences and Medicine, and John
Schmitz, Associate Professor of Medicine, and is overseen by an HCC Advisory Committee made up of
HCC members. Dr. Beumer leads and Dr. Schmitz actively participates in the weekly Merrill Egorin
Translational Research meeting, where HCC early drug development projects are discussed by an inter-
disciplinary group of basic, translational, and clinical scientists, thereby ensuring appropriate consideration
of CPPF’s role in these projects.
During this funding period, CPPF analyzed samples for a total of 36 unique investigators and provided
support for all 7 HCC research programs. During this funding period, CPPF developed 37 new assays, an
average of 22 assays were used per year, and more than 30,000 samples were analyzed (excluding
calibrators, quality controls or assay validation samples). CPPF supported 30 peer-reviewed grants and 70
publications, 30 of which were focused on clinical trials, and 19 of which focused on development of novel
assay methodologies.

## Key facts

- **NIH application ID:** 10024341
- **Project number:** 2P30CA047904-32
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** Jan Hendrik Beumer
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $220,455
- **Award type:** 2
- **Project period:** 1997-09-10 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10024341

## Citation

> US National Institutes of Health, RePORTER application 10024341, Cancer Pharmacokinetics and Pharmacodynamics Facility (2P30CA047904-32). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10024341. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*